ADCT logo

ADC Therapeutics S.A.

ADCT
Healthcare|Biotechnology|CH
$1.58
-0.06 (-3.66%)
Cash / Share
$1.41
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Apr 15, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (8)

Dec 2026
Est. completion
P1Chronic Lymphocytic Leukemia
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
NCT05971251n=24
Mar 2027
Est. completion
P2Relapsed or Refractory Large B-cell Lymphoma
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
NCT06788964n=29
Mar 2027
Est. completion
P1B-Cell Non-Hodgkin Lymphoma
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901n=154
Aug 2027
Est. completion
P2Follicular Lymphoma
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
NCT04998669n=100
Jun 2028
Est. completion
P2Marginal Zone Lymphoma
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
NCT05296070n=50
Nov 2029
Est. completion
P1Central Nervous System Lymphoma
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
NCT06607549n=12
Jan 2031
Est. completion
P2Large B-cell Lymphoma
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
NCT06919939n=26
May 2031
Est. completion
P2P3B-cell Non Hodgkin Lymphoma
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
NCT05991388n=210

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
P2
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
NCT05600686
May 2026
P2
Loncastuximab Tesirine in WM
NCT05190705
Mar 2026
P3
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484

Recent Press Releases

ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
Nov 4, 2026 · PRNewsWire
ADC Therapeutics to Present at November Investor Conferences
Nov 3, 2026 · PRNewsWire
ADC Therapeutics Announces New Employee Inducement Grant
Nov 2, 2026 · PRNewsWire
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
Nov 2, 2026 · PRNewsWire
ADC Therapeutics Announces ZYNLONTA® Updates in Japan
Oct 29, 2026 · PRNewsWire
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
Oct 8, 2026 · PRNewsWire
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Sep 3, 2026 · PRNewsWire
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
Aug 13, 2026 · PRNewsWire

SEC Filings (74)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 20268-KMaterial eventDocumentIndex
Nov 3, 2026S-4DocumentIndex
Oct 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 13, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 13, 2026S-8Employee stock planDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Jul 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 2, 20268-KMaterial eventDocumentIndex
Jun 24, 20268-KMaterial eventDocumentIndex
Jun 3, 20268-KMaterial eventDocumentIndex
Jun 2, 20268-KMaterial eventDocumentIndex
May 4, 202610-QQuarterly reportDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
Apr 24, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 20, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 20, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 15, 2026424B3Offering prospectusDocumentIndex
Apr 10, 2026PRE 14AProxy / shareholder voteDocumentIndex
Apr 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 16, 2026EFFECTDocumentIndex
Mar 16, 2026424B3Offering prospectusDocumentIndex
Mar 10, 2026S-3Shelf registrationDocumentIndex
Mar 10, 2026ARSAnnual report to holdersDocumentIndex
Mar 10, 202610-KAnnual reportDocumentIndex
Mar 10, 20268-KMaterial eventDocumentIndex
Feb 23, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Jan 8, 20268-KMaterial eventDocumentIndex
Dec 12, 2025EFFECTDocumentIndex
Dec 12, 2025424B3Offering prospectusDocumentIndex
Dec 9, 2025S-3/AShelf registrationDocumentIndex
Dec 5, 20258-KMaterial eventDocumentIndex
Nov 13, 2025SC 13G/APassive 5%+ stakeDocumentIndex